Science-Driven Strategy for BioPharma

Science-Driven Strategy for BioPharma

Catenion is a management consulting firm devoted to helping pharmaceutical and biotech companies implement more innovative and effective strategies.

What makes

us unique

  1. We focus on science-driven strategy: we answer key questions through comprehensive multidimensional assessments conducted by our team of life science PhDs.
  1. We have two decades of experience and relationships globally across the biopharmaceutical industry.
  1. We integrate Data Science in our analyses with a team of bioinformaticians, computational biologists and data engineers.

Therapeutic Area Strategy & Disease Mapping

Target Identification & Selection

Asset & Company Screening

Due Diligence

Corporate and R&D Strategy

R&D Risk Assessment

Portfolio Review & Prioritization

Science & Technology Mapping

Clinical Development Strategy

Indication Evaluation & Therapeutic Expansion/LCM

Hover the services to learn more.
catenion
catenion

We apply established workflows to evaluate projects and entire portfolios to support decision-making and prioritization.

catenion

We support companies to develop clinical development strategies that drive competitive differentiation through an adequate choice of trial design elements, such as powering, endpoints and comparators.

catenion

We have developed a structured approach to help companies adapt and design Corporate and R&D Strategies that link vision and goals.

catenion

Catenion’s proprietary ASAP is a structured and validated process to screen and select the most fitting companies or assets for potential acquisition or licensing.

catenion

We conduct an established and comprehensive process for the identification and prioritization of the most fitting and attractive biological targets for an asset or technology platform of interest.

catenion

We provide investors with thorough Commercial Due Diligences of lead assets of potential target companies.

catenion

Catenion’s proprietary Risk Assessment tool identifies technical and scientific risks of an R&D program based on over 500 criteria with pre-defined scores and weights.

catenion

We map landscapes for a given technology or type of therapy to distill strategic insights for our clients.

catenion

Our Therapeutic Expansion process allows for a systematic search, identification and prioritization of indications that best fit our client’s asset, in line with strategy and needs.

catenion

Our Disease Mapping evaluates the current state, future scenarios and opportunities of an indication or therapeutic area of interest and complements them with internal cross-functional capabilities.

Our Clients

& Testimonials

valo health 88945793
“Catenion is an outstanding partner. They deeply understand the needs of a client, work closely with the utmost professionalism and focus on key outcomes, with unwavering focus. Their insights are top notch across the board with true scientific rigor.”

David Berry

Valo Health / Flagship Pioneering

CEO / General Partner

Mkgaa768x432
“When dealing with strategic topics related to R&D, Catenion is my partner of choice. They bring unique perspectives and frameworks, and their deep rooting in science and technology clearly differentiates them from other consulting firms that I know.”

Dr. Stefan Oschmann

Merck KGaA

CEO

Logo Bayer
“One of the toughest decisions I had to take in my role as CEO of Bayer Pharma was to refocus our Discovery activities after the market withdrawal of Lipobay. Using their proprietary tools, benchmarks and a tough, fact–based approach, Catenion guided the Discovery management team through a difficult process of prioritisation of therapeutic areas and projects and provided crucial support for the decision making of the Bayer Corporate Board.”

Dr. Wolfgang Plischke

Bayer Pharma

CEO

Endocyte NovartisCo
“Catenion was able to identify and address the fundamental questions across every aspect of the value chain for each of the programs we assessed. Their insight into the science, regulatory landscape, manufacturing challenges, competitive dynamics, and commercial potential provided an objective understanding of the risks and opportunities.”

Mike Sherman

Endocyte

CEO

download 1
“We have successfully worked with Catenion on various strategic- and portfolio related- topics. They really go deep into the science and are able to translate insights into effective strategies. They are fully at home in the world of US biotech and have an extensive network in Europe and Japan.”

Jon P. Stonehouse

Biocryst Pharmaceuticals Inc.

President and CEO

Note: Affiliations at the time of the collaboration with Catenion.

Insights

In addition to our self-published insights, we also contribute to a variety of different journals on a number of topics. These articles can all be found below.

Catenion Markus Thunecke compressed
“We bridge science, technology and business, working directly with project teams, as well as senior management.”
Dr. Markus Thunecke
Senior Partner
Catenion Matthias Krings
“As trusted partners of top executives in Europe, the US and Japan, we are valued for our objectivity and independent thought.”
Dr. Matthias Krings
Senior Partner
Catenion Mariana Cerdeira 768x994 1
“We develop strategies that empower our clients to drive innovation and bring new treatments from promises to patients.”
Dr. Mariana Cerdeira
Manager
Catenion Arno Heuermann 2
“Translating new technologies into viable business ideas.”
Arno Heuermann
COO, Partner/Managing Director
Catenion Pascal Joly
“At Catenion, I can put my scientific background in cell therapy and regenerative medicine to practical use and help bring innovative therapies to the market.”
Dr. Pascal Joly
Principal
Catenion Ana Rita da Costa
“Catenion provides an exciting workplace where science meets business. We aim to help our clients to reach patients sooner and better.”
Dr. Ana Rita da Costa
Manager
Catenion Christian Elze
“Our uniqueness begins with a deep understanding of what really counts in the pharmaceutical and medical products industries.”
Christian Elze
Senior Partner
Catenion Simin Oz
“At Catenion’s Data Science Unit, we generate data-driven and customized knowledge bases to identify and prioritize indications and drug targets."
Dr. Simin Oz
Manager
Catenion Damir Omerbasic 768x994 1
“Working with clients to identify opportunities and implement solutions to the tough problems in biopharma R&D.”
Dr. Damir Omerbasic
Manager
Catenion Markus Thunecke compressed
“We bridge science, technology and business, working directly with project teams, as well as senior management.”
Dr. Markus Thunecke
Senior Partner
Catenion Matthias Krings
“As trusted partners of top executives in Europe, the US and Japan, we are valued for our objectivity and independent thought.”
Dr. Matthias Krings
Senior Partner
Catenion Mariana Cerdeira 768x994 1
“We develop strategies that empower our clients to drive innovation and bring new treatments from promises to patients.”
Dr. Mariana Cerdeira
Manager
Catenion Arno Heuermann 2
“Translating new technologies into viable business ideas.”
Arno Heuermann
COO, Partner/Managing Director
Catenion Pascal Joly
“At Catenion, I can put my scientific background in cell therapy and regenerative medicine to practical use and help bring innovative therapies to the market.”
Dr. Pascal Joly
Principal
Catenion Ana Rita da Costa
“Catenion provides an exciting workplace where science meets business. We aim to help our clients to reach patients sooner and better.”
Dr. Ana Rita da Costa
Manager
Catenion Christian Elze
“Our uniqueness begins with a deep understanding of what really counts in the pharmaceutical and medical products industries.”
Christian Elze
Senior Partner
Catenion Simin Oz
“At Catenion’s Data Science Unit, we generate data-driven and customized knowledge bases to identify and prioritize indications and drug targets."
Dr. Simin Oz
Manager
Catenion Damir Omerbasic 768x994 1
“Working with clients to identify opportunities and implement solutions to the tough problems in biopharma R&D.”
Dr. Damir Omerbasic
Manager

19

years

Catenion was founded in 2003 by its four senior partners. For over 19 years, we have been helping our clients develop actionable competitive strategies.

200

companies

companies

Catenion has worked with over 200 companies, from small biotechs to big pharma across the world.

1500

projects

Our consultants have successfully delivered more than 1500 projects over the years.

15+

languages

All together, our consultants speak 15+ languages, so wherever we are in the world, we connect with people and respect local cultures.

19

years

Catenion was founded in 2003 by its four senior partners. For over 19 years, we have been helping our clients develop actionable competitive strategies.

200

companies

companies

Catenion has worked with over 200 companies, from small biotechs to big pharma across the world.